ABCL Stock Recent News

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two drugs set for IND approval in 2025. AbCellera has a strong financial position and is trading at a relatively low cash multiple, making it an attractive investment in biotech.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Allison Bratzel - Piper Sandler Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Stephen Willey - Stifel Puneet Souda - Leerink Partners Steven Mah - Cowen Malcolm Hoffman - BMO Operator Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today's interactive broadcast.

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI stocks to invest in. At the moment, new drug development has a ridiculous fail rate of 90%, according to the National Institutes of Health.

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - Chief Executive Officer & President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Antonia Borovina - Bloom Burton Steven Mah - Cowen Stephen Willey - Stifel Malcolm Hoffman - BMO Gaurav Goparaju - Berenberg Operator Good afternoon, and thank you, and welcome to AbCellera's Second Quarter 2023 Business Update Conference Call. My name is Jason, and I will be the facilitator for the audio portion of today's interactive broadcast.

The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.